Evidence map›Paper›PMID 30227159›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2018

Using elongated microparticles to enhance tailorable nanoemulsion delivery in excised human skin and volunteers.

Miko Yamada, Hossam Tayeb, Hequn Wang, Nhung Dang, Yousuf H Mohammed, Sam Osseiran, Paul J Belt, Michael S Roberts, Conor L Evans, Frank Sainsbury and 1 more

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review.International journal of molecular sciences · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Miko YamadaFuture Industries Institute, University of South Australia, Adelaide, Australia; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute at the Princess Alexandra Hospital, Brisbane, Australia.
Hossam TayebAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Australia; Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Hequn WangWellman Centre for Photomedicine, Massachusetts General Hospital, Harvard Medical School, MA, USA.
Nhung DangFuture Industries Institute, University of South Australia, Adelaide, Australia; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute at the Princess Alexandra Hospital, Brisbane, Australia.
Yousuf H MohammedTherapeutic Research Centre, School of Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, Australia.
Sam OsseiranWellman Centre for Photomedicine, Massachusetts General Hospital, Harvard Medical School, MA, USA; Harvard-MIT Division of Health Sciences and Technology, MA, USA.
Paul J BeltDepartment of Plastic and Reconstructive Surgery and Orthopaedic Surgery, Princess Alexandra Hospital, Brisbane, Australia.
Michael S RobertsTherapeutic Research Centre, School of Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, Australia; School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.
Conor L EvansWellman Centre for Photomedicine, Massachusetts General Hospital, Harvard Medical School, MA, USA.
Frank SainsburyAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Australia. Electronic address: f.sainsbury@uq.edu.au.
Tarl W ProwFuture Industries Institute, University of South Australia, Adelaide, Australia; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute at the Princess Alexandra Hospital, Brisbane, Australia. Electronic address: tarl.prow@unisa.edu.au.

Funding

Wide-Field Short-Wave Infrared (SWIR) multiphoton (MP) tissue imagingP41EB015871 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SO, PETER T. · 2012 to 2021
$11.3M
CIHRNIBIB NIH HHS P41 EB015871
6 · The paper itself

Abstract

This study demonstrates, for the first time, clinical testing of elongated silica microparticles (EMP) combined with tailorable nanoemulsions (TNE) to enhance topical delivery of hydrophobic drug surrogates. Likewise, this is the first report of 6-carboxyfluorescein (a model molecule for topically delivered hydrophobic drugs) AM1 & DAMP4 (novel short peptide surfactants) used in volunteers. The EMP penetrates through the epidermis and stop at the dermal-epidermal junction (DEJ). TNE are unusually stable and useful because the oil core allows high drug loading levels and the surface properties can be easily controlled. At first, we chose alginate as a crosslinking agent between EMP and TNE. We initially incorporated a fluorescent lipophilic dye, DiI, as a hydrophobic drug surrogate into TNE for visualization with microscopy. We compared four different coating approaches to combine EMP and TNE and tested these formulations in freshly excised human skin. The delivery profile characterisation was imaged by dye- free coherent anti-Stoke Raman scattering (CARS) microscopy to detect the core droplet of TNE that was packed with pharmaceutical grade lipid (glycerol) instead of DiI. These data show the EMP penetrating to the DEJ followed by controlled release of the TNE. Freeze-dried formulations with crosslinking resulted in a sustained release profile, whereas a freeze-dried formulation without crosslinking showed an immediate burst-type release profile. Finally, we tested the crosslinked TNE coated EMP formulation in volunteers using multiphoton microscopy (MPM) and fluorescence-lifetime imaging microscopy (FLIM) to document the penetration depth characteristics. These forms of microscopy have limitations in terms of image acquisition speed and imaging area coverage but can detect fluorescent drug delivery through the superficial skin in volunteers. 6-Carboxyfluorescein was selected as the fluorescent drug surrogate for the volunteer study based on the similarity of size, charge and hydrophobicity characteristics to small therapeutic drugs that are difficult to deliver through skin. The imaging data showed a 6-carboxyfluorescein signal deep in volunteer skin supporting the hypothesis that EMP can indeed enhance the delivery of TNE in human skin. There were no adverse events recorded at the time of the study or after the study, supporting the use of 6-carboxyfluorescein as a safe and detectable drug surrogate for topical drug research. In conclusion, dry formulations, with controllable release profiles can be obtained with TNE coated EMP that can effectively enhance hydrophobic payload delivery deep into the human epidermis.

Indexed as

Drug Delivery SystemsEmulsionsHealthy VolunteersHumansNanoparticlesPeptidesSilicon DioxideSkinEmulsionsPeptidesSilicon Dioxide

Identifiers

PMID30227159
PMCPMC7050638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.